Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peripheral blood TCR marker for ovarian cancer as well as detection kit and application of peripheral blood TCR marker

A marker and ovarian cancer technology, applied in the field of genetic engineering, can solve the problems of less than 50% survival rate and inaccurate data, and achieve the effect of low labor cost, simple sampling, and reduced detection cost

Pending Publication Date: 2020-09-04
CHENGDU EXAB BIOTECH CO LTD
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the early diagnosis rate of ovarian cancer is about 25%, and 75% of the patients are diagnosed as III-IV stage of the International Federation of Obstetrics and Gynecology (FIGO), and the 5-year survival rate is less than 50%.
Tumor markers can only reflect physical changes through multiple dynamic detections, and a single data item has no accurate meaning

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peripheral blood TCR marker for ovarian cancer as well as detection kit and application of peripheral blood TCR marker
  • Peripheral blood TCR marker for ovarian cancer as well as detection kit and application of peripheral blood TCR marker
  • Peripheral blood TCR marker for ovarian cancer as well as detection kit and application of peripheral blood TCR marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1: Ovarian cancer TCR marker CDR3 sequence set was obtained by immunographic analysis

[0055] 1. Sampling and immune map analysis

[0056] Collect 1301 control groups (including healthy people and patients with non-tumor diseases, 1300 people for model building, 1 healthy person for verification), 101 ovarian cancer patients (100 people for model building, 1 person for verification) and the peripheral blood of a subject with unknown health status (10mL per person), and the amino acid sequence of the TCR epitope 3 (CDR3) of the subject and the control group was obtained by high-throughput sequencing to ensure the functionality of each sample The total number of CDR3 sequences of TCR should not be less than 30,000;

[0057] 2. The CDR3 sequence of the TCR of each sample is randomly sampled without replacement, so that the total number of CDR3 sequences of each sample is 30,000. For any specific CDR3 sequence X, the number of repeated occurrences in the single-s...

Embodiment 2

[0063] Example 2: Verification of the specificity of the ovarian cancer TCR marker CDR3 sequence set

[0064] 1. Sampling and immune map analysis

[0065] Peripheral blood (10 mL per person) was collected from 250 tumor patients without ovarian cancer and 107 subjects with unknown health status, and the epitope 3 (CDR3) amino acids of the TCR of the subjects and the control group were obtained by high-throughput sequencing Sequences, to ensure that the total number of CDR3 sequences of functional TCRs in each sample is not less than 30,000; random non-replacement sampling is performed on the CDR3 sequences of TCRs in each sample, so that the total number of CDR3 sequences in each sample is 30,000.

[0066] 2. Randomly select 100 healthy people and 45 non-tumor disease patients from the control group in Example 1.

[0067] 3. According to 100 healthy people, 45 non-tumor disease patients, and 100 ovarian cancer patients from Example 1, and 250 non-ovarian cancer tumor patients...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a peripheral blood TCR marker for ovarian cancer as well as a detection kit and application of the marker. The marker comprises at least one of proteins shown as SEQ ID NO.1-100 in sequence. The method is based on a high-throughput sequencing method and includes steps of: drawing only a small amount of peripheral blood, extracting RNA (Ribonucleic Acid), treating a sample to establish an immune map library, carrying out high-throughput sequencing and TCR data analysis, determining a characteristic TCR sequence in peripheral blood of the ovarian cancer, and then comparing a test result of the sample to be tested with the characteristic TCR sequence so as to determine whether the ovarian cancer exists or not. The marker can simultaneously compare a huge number of ovarian cancer specific TCR sequences, has higher specificity and accuracy compared with single detection of one or more markers, and improves the diagnosis efficiency.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and in particular relates to a peripheral blood TCR marker of ovarian cancer, a detection kit and application thereof. Background technique [0002] According to the latest statistics from the World Health Organization, the incidence of ovarian cancer ranks sixth among common tumors in women. In my country, the annual incidence of ovarian cancer ranks third in female reproductive system tumors, ranking third among cervical cancer and malignant tumors of the uterine body. After that, it showed an upward trend year by year. Ovarian cancer is one of the malignant tumors with the highest mortality rate in gynecological tumors. It is characterized by asymptomatic early stage. Most patients are already in the advanced stage when they are diagnosed, and their 5-year survival rate is only about 35%. Reasons: hidden onset, Early diagnosis is difficult. At present, the early diagnosis rate of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574A61K39/00A61P35/00
CPCG01N33/57449G01N33/57488A61K39/001111A61P35/00G01N2333/7051
Inventor 张志新卓越杨鑫钟雪梅高浩杨诗涵
Owner CHENGDU EXAB BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com